Lead Product(s): RNA-based medicines
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,250.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration May 11, 2021
MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly’s key therapeutic focus areas. Lilly will conduct preclinical and clinical activities of candidates and will retain commercialization rights.